Sanofi Mitigates Viscosupplement Sales Losses in 2Q19

Sanofi continues to correct course on its orthobiologics business, with a -5.4% revenue decline in 2Q19 after sustaining an almost -20% decline in 2018.

Quarterly Highlights

• Continued struggles in the U.S. were offset somewhat by high-single-digit growth in ex-U.S. markets.
• Sanofi seems to have stabilized its orthobiologics business after a span of four consecutive quarters with at least a -20% sales decline between 4Q17 and 3Q18. The average quarterly decline since then is -3.7%.

Performance by Segment

Synvisc and Synvisc-One sales on an as-reported basis are as follows ($MM).

Sales by Geographic Region

Synvisc and Synvisc-One sales by geographic region are as follows ($MM).

Sources: Sanofi

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.